Wanqing Iris Zhi, MD, PhD
Vice President
2026 - 2028
Dr. Iris Zhi, MD, PhD, is a breast medical oncologist and integrative oncology expert dedicated to improving patient outcomes and advancing clinical operations. She currently serves as the Medical Director of Clinical Operations in Medical Oncology at NYU Langone Perlmutter Cancer Center – Long Island and Associate Professor at NYU Grossman Long Island School of Medicine. Before joining NYU Langone, she was a member at the Breast Medicine Service at Memorial Sloan Kettering Cancer Center and served as the Regional Medical Director at MSK Commack, where she played a key role in expanding regional cancer care services. Dr. Zhi has been recognized for her excellence in oncology, research, and mentorship, earning multiple awards, including Top Doctors on Long Island (Newsday), the Lynn Sage Scholar/Fellow Award, the Society for Integrative Oncology New Investigator Award, the Stage IV Champion Award.
Dr. Zhi completed her medical degree at Peking University Health Science Center and earned her PhD in Biochemistry and Structural Biology from Stony Brook University. She completed her Internal Medicine residency at Nassau University Medical Center and pursued a Hematology and Medical Oncology fellowship at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, where she was an NIH T32 research fellow.
Dr. Zhi’s research focuses on breast cancer in older adults, novel systemic therapies, and integrative oncology. She has led clinical trials evaluating acupuncture for chemotherapy-induced peripheral neuropathy (CIPN) and has actively contributed to quality improvement initiatives that enhance patient access and operational efficiency. As a leader in both academia and clinical practice, Dr. Zhi is committed to fostering an inclusive oncology community, mentoring the next generation of oncologists, and driving operational efficiency to improve patient care. She advocates for interdisciplinary collaboration and innovative approaches that bridge academic and community oncology, ensuring equitable access to high-quality cancer care.